GNLX
Genelux Corporation
NASDAQ · Healthcare · Biotechnology · US
$2.44
−3.17%Next report
Analyst consensus
- Next report date
- Nov 4, 2026
- EPS estimate
- -$0.20
- Revenue estimate
- —
Latest reported
- Last report date
- Aug 13, 2026
- EPS actual
- -$0.21
- EPS estimate
- -$0.20
- Revenue actual
- —
- Revenue estimate
- —
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 2
- EPS misses (12Q)
- 9
- EPS in line (12Q)
- 1
- Avg surprise (4Q)
- -4.6%
- Revenue beats (12Q)
- 0
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Nov 4, 2026